Estellis 3mg+14.2mg Tablet

✔️ Estellis is taken as one tablet daily for 28 consecutive days, following a specific schedule:

Days 1-24: Take one pink active tablet at the same time each day.

Days 25-28: Take one white inactive tablet daily for four days.

✔️ Common side effects reported in ≥2% of users include:

• Menstrual irregularities (spotting, breakthrough bleeding, or amenorrhea)
• Mood changes (mood swings, depression, or irritability)
• Headache or migraines
• Breast tenderness or discomfort
• Painful periods (dysmenorrhea)
• Acne
• Weight gain
• Reduced libido

✔️ Instructions for Missed Doses:

If one pink active tablet is missed: Take the missed tablet as soon as possible, even if it means taking two tablets in one day. Continue with the remaining tablets as per schedule.

If two or more pink active tablets are missed (Week 1 or Week 2): Take one of the missed tablets immediately, followed by the scheduled tablet for the current day (this means taking two tablets on that day). The remaining missed tablets should be discarded. Continue taking one tablet per day until the pack is finished. Use additional non-hormonal contraception for the next 7 days.

If two pink active tablets are missed in Week 3: Take one missed tablet immediately, followed by the scheduled tablet for the current day. Discard any other missed tablets. Complete the active tablets and skip the inactive tablets. Start a new pack the next day. Additional contraception should be used for 7 days.

If an inactive (white) tablet is missed: Skip the missed tablet and continue taking one tablet per day until the pack is finished.

✔️ Vomiting or Acute Diarrhea After Taking a Tablet:

• If vomiting or severe diarrhea occurs within 3 to 4 hours of taking an active tablet, take another active tablet as soon as possible (preferably within 12 hours of the usual dosage time).
• If two or more tablets are missed due to vomiting or diarrhea, follow the instructions for missed doses and use backup contraception.
  (Always consult a registered medical practitioner before using this medication.)

✔️ Drug Interactions

CYP3A Inducers (e.g., certain antibiotics, antifungal agents, and anticonvulsants): These may reduce the effectiveness of Estellis by increasing the metabolism of its active ingredients, leading to breakthrough bleeding or contraceptive failure. Avoid concurrent use or ensure additional contraceptive measures for up to 28 days after stopping the CYP3A inducer.

✔️ Estellis is not recommended for individuals with:

• A history of arterial or venous thrombotic disorders (e.g., deep vein thrombosis, stroke, or heart attack).
• Hormone-sensitive cancers (such as breast cancer or endometrial cancer).
• Severe liver conditions including hepatic adenoma, liver cancer, acute hepatitis, or decompensated cirrhosis.
• Current or past abnormal uterine bleeding of unknown origin.
• Renal impairment or adrenal insufficiency.
• Concurrent use with certain hepatitis C treatments (e.g., ombitasvir/paritaprevir/ritonavir with or without dasabuvir), may lead to liver enzyme elevation.

✔️ Use During Pregnancy & Lactation

• Pregnancy: Estellis should be discontinued immediately if pregnancy is confirmed, as there is no benefit in using hormonal contraceptives during pregnancy.
• Breastfeeding: Hormonal contraceptives can pass into breast milk and may reduce milk production. If breastfeeding, it is recommended to consider non-hormonal contraceptive methods until weaning.

✔️ Precautions & Warnings

• Thrombosis Risk: If a patient develops a blood clot, stroke, or heart attack, Estellis should be stopped immediately. It should not be started earlier than 4 weeks postpartum.
• Hyperkalemia: If the patient is on long-term treatment with potassium-increasing medications (e.g., ACE inhibitors, NSAIDs, or potassium-sparing diuretics), monitor potassium levels during the first treatment cycle.
• Hypertension: Regularly monitor blood pressure. Discontinue use if blood pressure rises significantly.
• Migraines: If new, persistent, or severe migraines occur, stop taking Estellis.
• Hormone-Sensitive Cancers: If diagnosed with a hormonally sensitive malignancy, discontinue Estellis immediately.
• Liver Disease: Temporarily or permanently discontinue Estellis if there is significant liver enzyme elevation.
• Glucose & Lipid Metabolism: Monitor blood glucose in patients with diabetes or prediabetes. Consider alternative contraception in women with hypertriglyceridemia due to increased risk of pancreatitis.
• Gallbladder Disorders: If gallbladder or bile duct disease symptoms worsen, consider discontinuation.
• Menstrual Irregularities: May cause irregular bleeding or missed periods. If irregularities persist, further medical evaluation may be necessary.

✔️ Overdose Effects

Overdose symptoms may include nausea, vomiting, severe headaches, or unusual vaginal bleeding. In rare cases, overdose-related thromboembolic events (blood clots) may occur.

Pediatric accidental ingestion has been reported to cause nausea, drowsiness, or vaginal bleeding. Monitor potassium, sodium, and acid-base balance. In high-risk patients, short-term preventive anticoagulation therapy may be required.

✔️ Storage Conditions

• Store in a dry place at a controlled temperature between 20°C to 25°C.
• Protect from light and moisture to maintain effectiveness.
• Keep out of reach of children.